Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19597626 | 0.88 | ALDH1A1 (0.39) | LMNAALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL27094264 | 0.87 | ALDH1A1 (0.38) | DGAT1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL23294460 | 0.87 | DGAT1 (0.37) | DGAT1ALDH1A1MAPTMAPK1 | |
| SCHEMBL3023087 | 0.85 | DGAT1 (0.38) | DGAT1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL3636142 | 0.84 | DGAT1 (0.38) | DGAT1MAPT | |
| SCHEMBL18676310 | 0.84 | LMNA (0.35) | LMNAALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL15897825 | 0.81 | DGAT1 (0.39) | DGAT1LMNAALDH1A1MAPTTARBP2 | |
| SCHEMBL4802111 | 0.80 | CYP1A2 (0.46) | DGAT1LMNAALDH1A1MAPTHSD17B10 | |
| SCHEMBL14255842 | 0.80 | ALDH1A1 (0.44) | DGAT1LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL3528543 | 0.78 | MAPT (0.43) | DGAT1LMNAALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3363434-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970131-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DGAT1 691/4885LMNA 3836/4885ALDH1A1 545/4885 |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DGAT1 691/4885LMNA 3836/4885ALDH1A1 545/4885 |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DGAT1 691/4885LMNA 3836/4885ALDH1A1 545/4885 |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DGAT1 691/4885LMNA 3836/4885ALDH1A1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.